A Comparison of Two Sedation Techniques in Children Undergoing Transthoracic Echocardiography (TTE)

Heart Disease Clinical Trial

Official title:

A Qualitative Comparison of Two Sedation Techniques in Children Undergoing Transthoracic Echocardiography

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02250820
• Other study ID #: 2014-5961
• Status: Completed
• Phase: Phase 1
• Start date: November 2014
• Est. completion date: December 2017

Study information

• Verified date: January 2020
• Source: Children's Hospital Medical Center, Cincinnati
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will examine the quality of two sedation techniques (dexmedetomidine and pentobarbital) used for children aged 3 to 24 months who are undergoing a transthoracic echocardiography (TTE).

Description:

Currently there are two sedation methods used for children less than 24 months of age undergoing transthoracic echocardiography (TTE).

• One method provides sedation by mouth with the drug pentobarbital,

• The other provides sedation through the nose with the drug dexmedetomidine.

The choice of which method is used is based on evaluation of the patient's medical history and the preference of the anesthesiologist. To our knowledge, no study has compared these two sedation techniques for quality of care. The proposed study will help us determine which method yields the best quality and will allow us to improve the healthcare experience of our patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 280
• Est. completion date: December 2017
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Months to 24 Months

Eligibility

Inclusion Criteria:

• Outpatients, scheduled to receive sedation for elective transthoracic echocardiography

• The subject must be a candidate for both anesthetic techniques. A staff member of the Division of Cardiac Anesthesiology will make this decision.

• The subjects must be 3 months to 24 months (inclusive of the 24th month).

• The subject's legally authorized representative has given written informed consent to participate in the study.

Exclusion Criteria:

• The subject has a history of cardiac conduction system disease (e.g. 1st or 2nd degree Atrioventricular block) or channelopathy (e.g. long QT syndrome).

• The subject is taking digoxin, alpha-adrenergic or beta-adrenergic agonist or antagonist (e.g., clonidine, propranolol, albuterol), anti-arrhythmic medications, or vasodilators (e.g. ACE inhibitors) on the day of the study procedures. It is routine for children taking these medications to hold them on the day of their procedure, as requested by the clinical team.

• The subject has received a dose of any other sedative within 48 hours.

• The subject has life-threatening, medical conditions (American Society of Anesthesiologists Physical Status 4, 5). The American Society of Anesthesiologists (ASA) classification scale is a measure of physical status or how healthy the patient is. For our study, we will focus on children which are defined as ASA I, II or III which means a healthy child (ASA I), a child with a systemic disease that is mild and well controlled (ASA II) or a child with systemic disease that is severe and controlled (ASA III).

• The subject is allergic to or has a contraindication to any of the drugs or masking flavored syrup used in the study.

• The subject has previously been treated under this protocol.

• The subject has Trisomy 21 (exaggerated risk of bradycardia)

• The subject has severe coarctation of the aorta (risk of exaggerated vasoconstriction)

• The subject has Moyamoya disease (risk of recurrent stroke)

Related Conditions & MeSH terms

• Heart Disease
• Heart Diseases

Intervention

Drug:
• Dexmedetomidine
Nasal administration
• Pentobarbital
Oral administration

Other:
• Oral Placebo
Oral placebo will be cherry syrup
• Nasal Placebo
Nasal placebo will be nasally atomized saline

Locations

Country	Name	City	State
United States	Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Children's Hospital Medical Center, Cincinnati

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sedation Quality	The primary outcome variable will be the sedation quality for the first 60 minutes after sedation drug is administered. It will be assessed if child is sedated within 30 minutes of administration of sedative drug, and if sedation is maintained for at least 30 minutes to allow a detailed transthoracic echocardiographic study. Sedation is defined as achieving Ramsay sedation level >3.	60 minutes
Secondary	Time to sedation	Time from first dose of sedative medication to sedation. Sedation is defined as achieving Ramsay sedation level >3.	Participants will be followed for the time it takes to reach a sedated state, an expected average of 30 minutes
Secondary	Delirium prior to sedation	The incidence of delirium prior to achieving sedation.	Participants will be followed for the time it takes to reach a sedated state, an expected average of 30 minutes
Secondary	Duration of sedation level >3		Participants will be followed for the duration of the procedure, an expected average of 1 hour
Secondary	Sonographer Pauses	The number of sonographer pauses over 2 minutes due to patient movement or medical intervention will be counted.	Participants will be followed for the duration of the procedure, an expected average of 1 hour
Secondary	Need for rescue nasal Dexmedetomidine	The incidence of need for rescue nasal dexmedetomidine, due to patient arousal or movement prior to completion of TTE.	Participants will be followed for the duration of the procedure, an expected average of 1 hour
Secondary	Incidence-severity of respiratory complications	We will document the incidence and severity of respiratory complications (including supplemental oxygen).	Participants will be followed for the duration of their outpatient hospital stay, an expected average of 2 hours
Secondary	Vital sign deviations of more than 30% from baseline	We will document the incidence of blood pressure or heart rate deviations of more than 30% from baseline. Baseline will be measured prior to sedative administration.	Participants will be followed for the duration of their outpatient hospital stay, an expected average of 2 hours
Secondary	Post anesthesia drowsiness or agitation	We will document the incidence-severity of post anesthesia drowsiness or agitation.	Participants will be followed for the duration of their post procedure stay, an expected average of 1 hour
Secondary	Duration of Post Anesthesia Care Unit (PACU) Phase	We will document the duration of stay in Post Anesthesia Care Unit (PACU) phase in minutes.	Participants will be followed for the duration of their post procedure stay, an expected average of 1 hour
Secondary	Time to oral fluid intake	We will document the time (in minutes) to oral fluid intake during the PACU phase	Participants will be followed for the duration of their post procedure stay, an expected average of 1 hour
Secondary	Time to discharge	We will document the time it takes a patient to be discharged from the hospital after the completion of the TTE.	Participants will be followed for the duration of their post procedure stay, an expected average of 1 hour
Secondary	Satisfaction of the Parents	The satisfaction of the sedation technique will be completed by the parents by asking a series of questions during a follow-up phone call the next business day after the TTE.	up to 3 days